4.45
price up icon4.34%   0.185
after-market アフターアワーズ: 4.45
loading
前日終値:
$4.265
開ける:
$4.3
24時間の取引高:
526.58K
Relative Volume:
0.48
時価総額:
$303.35M
収益:
-
当期純損益:
$-27.03M
株価収益率:
-7.9464
EPS:
-0.56
ネットキャッシュフロー:
$-23.97M
1週間 パフォーマンス:
+2.30%
1か月 パフォーマンス:
+12.37%
6か月 パフォーマンス:
-14.75%
1年 パフォーマンス:
+104.13%
1日の値動き範囲:
Value
$4.30
$4.53
1週間の範囲:
Value
$4.095
$4.53
52週間の値動き範囲:
Value
$2.13
$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name
名前
Corvus Pharmaceuticals Inc
Name
セクター
Healthcare (1161)
Name
電話
(650) 900-4520
Name
住所
863 MITTEN ROAD, BURLINGAME, CA
Name
職員
31
Name
Twitter
Name
次回の収益日
2025-03-25
Name
最新のSEC提出書
Name
CRVS's Discussions on Twitter

CRVS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CRVS
Corvus Pharmaceuticals Inc
4.45 335.45M 0 -27.03M -23.97M -0.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-02 開始されました H.C. Wainwright Buy
2023-08-18 開始されました Oppenheimer Outperform
2021-12-01 再開されました Jefferies Buy
2021-05-27 開始されました Cantor Fitzgerald Overweight
2021-02-10 ダウングレード Mizuho Buy → Neutral
2019-09-12 開始されました Mizuho Buy
2019-05-29 開始されました ROTH Capital Buy
2017-08-24 アップグレード Credit Suisse Underperform → Neutral
2017-05-01 ダウングレード Credit Suisse Neutral → Underperform
2016-04-18 開始されました Credit Suisse Outperform
2016-04-18 開始されました Guggenheim Buy
すべてを表示

Corvus Pharmaceuticals Inc (CRVS) 最新ニュース

pulisher
Jul 21, 2025

Corvus Pharmaceuticals Inc. Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

What analysts say about Corvus Pharmaceuticals Inc. stockExplosive trading growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

What drives Corvus Pharmaceuticals Inc. stock priceTremendous growth opportunities - Jammu Links News

Jul 19, 2025
pulisher
Jul 18, 2025

Is Corvus Pharmaceuticals Inc. a good long term investmentRapidly expanding wealth - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 15, 2025

Why Corvus Pharmaceuticals Inc. stock attracts strong analyst attentionReal Time Alert Service - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Corvus Pharmaceuticals Inc. stock price move sharplyDouble Your Capital Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Corvus Pharmaceuticals Inc. stock performs during market volatilityDaily Breakout Picks - Newser

Jul 15, 2025
pulisher
Jul 08, 2025

Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says - MarketScreener

Jul 08, 2025
pulisher
Jul 03, 2025

Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis - TipRanks

Jul 03, 2025
pulisher
Jul 02, 2025

Corvus Pharmaceuticals: Insider Confidence and Clinical Catalysts Fueling Growth - AInvest

Jul 02, 2025
pulisher
Jul 01, 2025

OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million By Investing.com - Investing.com Canada

Jul 01, 2025
pulisher
Jun 30, 2025

Corvus Pharmaceuticals, Inc.(NasdaqGM: CRVS) added to Russell 3000 Index - MarketScreener

Jun 30, 2025
pulisher
Jun 25, 2025

Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan

Jun 25, 2025
pulisher
Jun 18, 2025

Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView

Jun 11, 2025
pulisher
Jun 10, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jun 10, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire

Jun 04, 2025
pulisher
May 28, 2025

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 28, 2025
pulisher
May 28, 2025

Exclusive: Corvus Pharmaceuticals Reveals Latest Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN

May 20, 2025
pulisher
May 20, 2025

CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating - Investing.com

May 20, 2025
pulisher
May 13, 2025

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World

May 13, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals (CRVS) Sees Notable Increase in Borrow Ra - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Spotlight On Top Penny Stocks For May 2025 - simplywall.st

May 12, 2025

Corvus Pharmaceuticals Inc (CRVS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
大文字化:     |  ボリューム (24 時間):